Cost of Illness in Inflammatory Bowel Disease

Background Frequent relapses sometimes necessitating hospitalization and the absence of pharmacological cure contribute to substantial healthcare costs in inflammatory bowel diseases (IBDs). The costs of health care in Indian patients with IBD are unknown. Aim To evaluate the annual costs for treati...

Full description

Saved in:
Bibliographic Details
Published in:Digestive diseases and sciences 2017-09, Vol.62 (9), p.2318-2326
Main Authors: Kamat, Nagesh, Ganesh Pai, C., Surulivel Rajan, M., Kamath, Asha
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Biochemistry
Colon
Cost of Illness
Crohn's disease
Economic aspects
Female
Follow-Up Studies
Gastroenterology
Hepatology
Hospitalization
Humans
India - epidemiology
Inflammatory bowel disease
Inflammatory Bowel Diseases - economics
Inflammatory Bowel Diseases - epidemiology
Inflammatory Bowel Diseases - therapy
Male
Medical care, Cost of
Medicine
Medicine & Public Health
Middle Aged
Oncology
Original Article
Prospective Studies
Transplant Surgery
Ulcerative colitis
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Frequent relapses sometimes necessitating hospitalization and the absence of pharmacological cure contribute to substantial healthcare costs in inflammatory bowel diseases (IBDs). The costs of health care in Indian patients with IBD are unknown. Aim To evaluate the annual costs for treating Crohn’s disease and ulcerative colitis. Methods A prevalence-based, micro-costing method was used to assess the components of annual costs in a prospective, observational study conducted in a tertiary healthcare center enrolled over a 24-month period beginning of July 2014. Results At enrollment, 43/59 (72.88%) patients with UC and 18/25 (72%) with CD were in remission. The annual median (IQR) cost per UC and CD patient in remission was INR 43,140 (34,357–51,031) [USD $707 (563–836)] and INR 43,763.5 (32,202–57,372) [USD $717 (527–940)], respectively, and in active disease was INR 52,436.5 (49,229–67,567.75) [$859 (807–1107)] and INR 72,145 (49,447–92,212) [USD $1182 (811–1512)], respectively. Compared with remission, active disease had a 1.4-fold higher cost for CD as compared to UC. In both groups, the greatest component of direct costs was drugs. Thirteen (22%) and 7 (28%) patients with UC and CD needed hospitalization accounting for 23.1 and 20.4% of the total costs, respectively. At one year, direct costs surmounted indirect costs in UC and CD ( p  
ISSN:0163-2116
1573-2568
DOI:10.1007/s10620-017-4690-z